The Study of Warfarin Maintenance Dose in Chinese Patients

Clinical Study of the Relationship Between Pharmacogenomics and Warfarin Dose in Chinese Patients

1. Title: Clinical study of the relationship between Pharmacogenomics and warfarin dose in Chinese patients
2. Drug: Warfarin
3. Design: To value the accuracy of warfarin Pharmacogenomics algorithm by the algorithm calculated dose and actual dose in the Chinese patients.
4. Hypothesis:Pharmacogenomic algorithm guided dose can help to predict warfarin dose in Chinese patients.

• For the patients who need to use warfarin, detect the "Vitamin K epoxide reductase complex subunit 1 (VKORC1),cytochrome p450 2C9 (CYP2C9), and cytochrome p450 4F2 (CYP4F2) genotype.
• Record the demographic information: gender, age, height, and weight.
• Record drug combination, complications, and international normalized ratio (INR), liver function and kidney function or other biochemical test results.
• Put genotypes, demographic information and other clinical information into the algorithm to calculate warfarin dose for the patients, and compared with the actual dose.

Inclusion Criteria:

• Chinese patients
• Age >18y
• target INR 1.5~3.0
• Patients signed informed consent

Exclusion Criteria:

• Has hemorrhage disease, or tendency to significant bleeding
• Severe liver and kidney disfunction, serious infections, severe heart failure (NYHA heart function classification Ⅲ magnitude), severe pulmonary hypertension, abnormal thyroid function, respiratory failure, anemia, malignant tumor, blood disease
• patients with pregnancy or lactation;
• with cognitive impairment.